Literature DB >> 15720795

A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental data.

Trachette L Jackson1.   

Abstract

Considerable research is aimed at determining the mechanisms by which hormone-refractory prostate cancer develops. In an effort to assist in the understanding of recurrent prostate cancer and the cellular processes that mediate this disease, a mathematical model is presented that describes both the pretreatment growth and the posttherapy relapse of human prostate cancer xenografts. Our goal is to evaluate the interplay between the multiple mechanisms that have been postulated as causes of androgen-independent relapse. Simulations of the model show that molecular events that render the androgen receptor irrelevant to disease progression, such as upregulation of BCL2, can result in relapse after androgen deprivation therapy. However, decreased apoptosis of androgen-independent cells alone overestimates the effects of hormone therapy when compared to experimental data. When decreased apoptosis is combined with continual androgen receptor activation, the posttherapy growth dynamics are in excellent correlation with experimental observations of the growth of LuCaP xenografts. Furthermore, the mathematical model predicts that upregulation of the androgen receptor, together with its increased activation, is alone sufficient to result in the androgen-independent growth of LNCaP xenografts. Recent experimental studies that suggest that the posttherapy increase in and continual activation of the androgen receptor are common and crucial features of recurrent prostate cancer provide validation of the model predictions. This approach provides a framework for using mathematical techniques to study novel therapeutic strategies aimed at controlling this disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15720795      PMCID: PMC1531673          DOI: 10.1593/neo.04259

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  22 in total

Review 1.  Hormone refractory prostate cancer.

Authors:  E D Crawford; M Rosenblum; A M Ziada; P H Lange
Journal:  Urology       Date:  1999-12       Impact factor: 2.649

2.  A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy.

Authors:  T L Jackson; H M Byrne
Journal:  Math Biosci       Date:  2000-03       Impact factor: 2.144

Review 3.  Endocrine treatment in prostate cancer.

Authors:  L J Denis; K Griffiths
Journal:  Semin Surg Oncol       Date:  2000 Jan-Feb

4.  Cancer statistics, 2000.

Authors:  R T Greenlee; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  2000 Jan-Feb       Impact factor: 508.702

Review 5.  Prostate cancer update.

Authors:  Brian I Rini; Eric J Small
Journal:  Curr Opin Oncol       Date:  2002-05       Impact factor: 3.645

6.  Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft.

Authors:  C W Gregory; R T Johnson; S C Presnell; J L Mohler; F S French
Journal:  J Androl       Date:  2001 Jul-Aug

7.  Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.

Authors:  C Palmberg; P Koivisto; L Kakkola; T L Tammela; O P Kallioniemi; T Visakorpi
Journal:  J Urol       Date:  2000-12       Impact factor: 7.450

8.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.

Authors:  C W Gregory; B He; R T Johnson; O H Ford; J L Mohler; F S French; E M Wilson
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

9.  Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model.

Authors:  Tsukasa Igawa; Fen-Fen Lin; Ming-Shyue Lee; Dev Karan; Surinder K Batra; Ming-Fong Lin
Journal:  Prostate       Date:  2002-03-01       Impact factor: 4.104

10.  Long-term effects of androgen deprivation therapy in prostate cancer patients.

Authors:  Shehzad Basaria; John Lieb; Alice M Tang; Theodore DeWeese; Michael Carducci; Mario Eisenberger; Adrian S Dobs
Journal:  Clin Endocrinol (Oxf)       Date:  2002-06       Impact factor: 3.478

View more
  14 in total

1.  Mathematical modeling of prostate cancer progression in response to androgen ablation therapy.

Authors:  Harsh Vardhan Jain; Steven K Clinton; Arvinder Bhinder; Avner Friedman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-21       Impact factor: 11.205

2.  Mechanistic modelling of prostate-specific antigen dynamics shows potential for personalized prediction of radiation therapy outcome.

Authors:  Guillermo Lorenzo; Víctor M Pérez-García; Alfonso Mariño; Luis A Pérez-Romasanta; Alessandro Reali; Hector Gomez
Journal:  J R Soc Interface       Date:  2019-08-14       Impact factor: 4.118

Review 3.  Mathematically modelling and controlling prostate cancer under intermittent hormone therapy.

Authors:  Yoshito Hirata; Gouhei Tanaka; Nicholas Bruchovsky; Kazuyuki Aihara
Journal:  Asian J Androl       Date:  2012-01-09       Impact factor: 3.285

4.  Nonlinear modelling of cancer: bridging the gap between cells and tumours.

Authors:  J S Lowengrub; H B Frieboes; F Jin; Y-L Chuang; X Li; P Macklin; S M Wise; V Cristini
Journal:  Nonlinearity       Date:  2010

5.  The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model.

Authors:  Steffen E Eikenberry; John D Nagy; Yang Kuang
Journal:  Biol Direct       Date:  2010-04-20       Impact factor: 4.540

6.  The role of transforming growth factor-beta-mediated tumor-stroma interactions in prostate cancer progression: an integrative approach.

Authors:  David Basanta; Douglas W Strand; Ralf B Lukner; Omar E Franco; David E Cliffel; Gustavo E Ayala; Simon W Hayward; Alexander R A Anderson
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

7.  A partial differential equation model and its reduction to an ordinary differential equation model for prostate tumor growth under intermittent hormone therapy.

Authors:  Youshan Tao; Qian Guo; Kazuyuki Aihara
Journal:  J Math Biol       Date:  2013-08-28       Impact factor: 2.259

8.  Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression.

Authors:  Yoshito Hirata; Koichiro Akakura; Celestia S Higano; Nicholas Bruchovsky; Kazuyuki Aihara
Journal:  J Mol Cell Biol       Date:  2012-05-04       Impact factor: 6.216

9.  Modeling the synergistic properties of drugs in hormonal treatment for prostate cancer.

Authors:  Trevor Reckell; Kyle Nguyen; Tin Phan; Sharon Crook; Eric J Kostelich; Yang Kuang
Journal:  J Theor Biol       Date:  2021-01-07       Impact factor: 2.691

10.  Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy.

Authors:  Yoshito Hirata; Kai Morino; Koichiro Akakura; Celestia S Higano; Nicholas Bruchovsky; Teresa Gambol; Susan Hall; Gouhei Tanaka; Kazuyuki Aihara
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.